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In order to identify the key signaling pathways regulated by
the merlin tumor suppressor protein, previous studies have
focused on merlin growth regulation in fibroblasts, primary
Schwann cell and human schwannoma cell cultures, meningioma and schwannoma tumor cell lines, and other non-central
nervous system (non-CNS) cell types. These investigations
have resulted in the identification of a large number of nonintersecting growth control pathways regulated by merlin in
different cell types. In this regard, merlin has been implicated
in epidermal growth factor receptor (EGFR) (9), ␤1-integrin
(15), and CD44 (1, 35, 48) function as well as in Ras (25, 59),
Rac1 (34, 52), phosphatidylinositol 3-kinase (44), mitogenactivated protein kinase (MAPK) (7, 30), and STAT (51) intracellular signaling. While each of these pathways is involved
in growth control in the brain, it is not known which of these
intracellular signaling pathways are deregulated in NF2-deficient CNS cell types.
To gain insights into the role of the NF2 gene in glial cell
growth control relevant to the development of targeted therapies for NF2-associated glial cell malignancies, we studied
the consequence of merlin loss on the growth of primary
brain glial cells (astrocytes) in vitro and in vivo, using Nf2
conditional knockout genetically engineered mice (GEM).
We demonstrate for the first time that merlin regulates
brain glial cell growth by controlling the phosphorylation/
activity of Src and its downstream effectors, FAK and paxillin. Furthermore, we show that merlin regulation of Src
phosphorylation/activation is modulated by ErbB2 phosphorylation/activation and ErbB2-Src binding. Finally, we show
that merlin competitively inhibits Src binding to ErbB2 and,
in this manner, prevents ErbB2-mediated Src phosphorylation and downstream mitogenic signaling. Based on these
findings, we propose a novel mechanism for merlin growth
regulation in CNS glia.

Neurofibromatosis type 2 (NF2) is an autosomal dominant
inherited cancer syndrome in which affected individuals develop nervous system tumors, including peripheral nerve tumors (schwannomas), leptomeningeal tumors (meningiomas),
and glial fibrillary acidic protein (GFAP)-immunoreactive glial
cell tumors (spinal ependymomas). NF2 results from a germ
line mutation in the NF2 tumor suppressor gene, located on
chromosome 22q (46, 60). Tumors in this disorder arise following somatic inactivation of the one remaining wild-type
(WT) NF2 allele in specific cell types. In this regard, NF2associated schwannomas, meningiomas, and ependymomas all
exhibit biallelic NF2 gene inactivation (33, 47, 61). In addition,
NF2 gene inactivation is also observed in 50 to 78% of sporadic
schwannomas, 32 to 84% of sporadic meningiomas, and 37%
of sporadic ependymomas (21, 29), suggesting that this gene is
also a key growth regulator in nonhereditary nervous system
cancers.
The NF2 gene was identified in 1993 and found to code for
a 595-amino-acid protein, termed merlin or schwannomin (46,
60). Analysis of the predicted protein sequence revealed striking sequence similarity between merlin and a family of protein
4.1 family members that link the actin cytoskeleton to cell
surface glycoproteins (55). In particular, merlin most closely
resembles the ezrin/radixin/moesin (ERM) subfamily and has
been shown to bind actin as well as to associate with several
cell surface glycoproteins, including CD44 and ␤1-integrin (5,
32, 48). However, unlike the ERM proteins, merlin is unique in
its capacity to function as a nervous system tumor suppressor
gene.
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Individuals with the inherited cancer predisposition syndrome neurofibromatosis 2 (NF2) develop several central
nervous system (CNS) malignancies, including glial cell neoplasms (ependymomas). Recent studies have suggested
that the NF2 protein, merlin (or schwannomin), may regulate receptor tyrosine kinase signaling, intracellular
mitogenic growth control pathways, or adherens junction organization in non-nervous-system cell types. For this
report, we used glial fibrillary acidic protein conditional knockout mice and derivative glia to determine how merlin
regulates CNS glial cell proliferation. We show that the loss of merlin in glial cells results in increased proliferation
in vitro and in vivo. Merlin regulation of glial cell growth reflects deregulated Src activity, such that pharmacologic
or genetic inhibition of Src activation reduces Nf2ⴚ/ⴚ glial cell growth to wild-type levels. We further show that Src
regulates Nf2ⴚ/ⴚ glial cell growth by sequentially regulating FAK and paxillin phosphorylation/activity. Next, we
demonstrate that Src activation results from merlin regulation of ErbB2 activation and that genetic or pharmacologic ErbB2 inhibition reduces Nf2ⴚ/ⴚ glial cell Src/Src effector activation and proliferation to wild-type levels.
Lastly, we show that merlin competes with Src for direct binding to ErbB2 and present a novel molecular
mechanism for merlin regulation of ErbB2-dependent Src signaling and growth control.
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MATERIALS AND METHODS

vector) retrovirus were generated in 293T cells. Transduced glia were evaluated
by fluorescence microscopy using a microscope equipped with a digital camera.
More than 90% of glial cells displayed GFP expression, indicative of effective
transduction. Merlin expression was confirmed by immunoblotting with a commercially available merlin antibody (NF2 C-18; 1:1,000 dilution).
Immunoblotting. Untreated or reagent-treated primary glia and brains were
lysed in NP-40 lysis buffer (50 mM Tris [pH 7.0], 150 mM NaCl, 0.5% NP-40, 1
mM dithiothreitol [DTT]) with protease inhibitors (leupeptin, benzamidine,
aprotinin, and phenylmethylsulfonyl fluoride). Proteins were separated by SDSpolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) prior to detection with
antibodies against phosphorylated Src-Y416, FAK-Y576/577 (Cell Signaling
Technology, Beverly, MA) (1:1,000 dilution), ErbB2-Y877 (Abcam, Cambridge,
MA) (1:1,000 dilution), and paxillin-Y118 (Cell Signaling Technology, Beverly,
MA) (1:1,000 dilution). Antibodies against total Src, FAK, ErbB2, and paxillin
(from the same manufacturers and at the same dilutions as the phospho-specific
antibodies), as well as ␣-tubulin (Sigma) (1:5,000 dilution), were used as controls
for equal protein loading and quantitation. Antibodies against phosphorylated
MAPK p44/p42, AKT-T308, and EGFR-Y845 as well as total MAPK p44/p42,
AKT, and EGFR were purchased from Cell Signaling Technology and used at a
1:1,000 dilution. Densitometric analysis was performed using Gel-Pro Analyzer
4.0 software (MediaCybernetics, Silver Spring, MD) with anti-tubulin or nonphospho-Src, -paxillin, -FAK, and -ErbB2 antibodies as internal loading controls.
Immunoprecipitation. Primary glia were lysed by sonication in precipitation
lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate,
1 mM Na3VO4, 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride). Antibodies against Src (U.S. Biological) (1:100 dilution) or ErbB2 (Upstate, Temecula, CA) (1:100 dilution) were added to the lysates and incubated with gentle
rocking overnight at 4°C. Protein A-agarose beads (Calbiochem) were then
added to the mixture and rotated for 4 hours. Beads were washed with precipitation lysis buffer and resuspended in 2⫻ Laemmli buffer. Each sample was then
boiled and resolved by SDS-PAGE, followed by immunoblot analysis as described above.
Tyrosine phosphorylation was detected following incubation of cell lysates
with agarose-conjugated monoclonal anti-phosphotyrosine (PY20) antibody
(Sigma) according to the manufacturer’s protocols. Following washes, proteins
were eluted by boiling in gel loading buffer and detected by immunoblotting
using antibodies against Ack1 (Cell Signaling Technology) (1:1,000 dilution),
p130CAS (Sigma) (1:1,000 dilution), CASPR (Santa Cruz Biotechnology) (1:500
dilution), ErbB3 (Cell Signaling Technology) (1:1,000 dilution), and ErbB4 (Cell
Signaling Technology) (1:1,000 dilution).
Src and ErbB2 kinase activity assays. Primary glial cells were lysed by sonication in precipitation lysis buffer. Antibodies against Src (Cell Signaling) (1:50
dilution) or ErbB2 (Cell Signaling) (1:50 dilution) were added to the lysates and
incubated with gentle rocking overnight at 4°C. Protein G agarose beads (Calbiochem) were then added to the mixture and rotated overnight. Beads were
washed and resuspended in 50 l of 1⫻ kinase buffer containing signal transduction protein Tyr160-biotinylated peptide substrate (1.5 M; Cell Signaling),
20 M ATP, and 1.25 M DTT for Src or FLT3 Tyr589-biotinylated peptide (1.5
M; Cell Signaling), 20 M ATP, and 1.25 M DTT for ErbB2. After 30 min,
each reaction was stopped by the addition of EDTA. Twenty-five microliters of
each reaction mix was added to a 96-well streptavidin-coated plate containing 75
l distilled H2O/well and incubated at room temperature for 60 min. After the
plates were washed with PBS-Tween 20 (PBS-T), 100 l of diluted detection
antibody (phosphotyrosine monoclonal antibody [MAb] P-Tyr-100 [1:500 dilution] in PBS-T with 1% bovine serum albumin) was added to each well for 2 h
at 37°C. Next, 100 l of horseradish peroxidase-labeled mouse secondary antibody (1:500 in PBS-T with 1% bovine serum albumin; Cell Signaling) was added,
and the plates were incubated at room temperature for 30 min, washed with
PBS-T, and developed in 100 l TMB solution (Cell Signaling) for 10 min at
37°C. Following the addition of stop solution (Cell Signaling), the absorbance
was read at 450 nm.
Rac1 activation assay. Rac activation in WT and Nf2⫺/⫺ glial cell lysates was
determined using a Rac1 activation assay kit (Upstate Biotechnologies, Temecula, CA) according to the manufacturer’s instructions, as previously described (17).
In vitro binding assays. A commercially available TnT quick coupled transcription/translation system (Promega, Madison, WI) was used as previously described
(20) to transcribe and translate WT merlin (NF2.WT), mutant merlin (NF2.L64P),
a C-terminal merlin fragment containing residues 300 to 595 (NF2.C-term), an
N-terminal merlin fragment containing residues 1 to 300 (NF2.N-term), a merlin
fragment containing residues 300 to 557 (NF2.300-557), and WT Src (Src) in the
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Cell culture. Forebrain glial cell cultures from postnatal day 3 Nf2flox/flox mice
(18) were generated as previously described (24, 49). Briefly, forebrains were
isolated and enzymatically digested with 0.25% trypsin for 10 min at 37°C. Cells
were then placed in modified Eagle’s medium with 10% fetal bovine serum and
grown for 2 weeks to generate cultures composed of ⬎97% GFAP-immunoreactive cells (glia). Adenovirus type 5 (Ad5) viruses, namely, Ad5-LacZ and
Ad5-Cre (University of Iowa Gene Transfer Core, Iowa City, IA), were used to
produce control (WT) and Nf2-deficient (Nf2⫺/⫺) glia, respectively, according to
protocols described previously in our laboratory (10, 49). Merlin loss was confirmed by immunoblot analysis using a rabbit polyclonal NF2 antibody (NF2
C-18; Santa Cruz Biotechnology, Santa Cruz, CA) (1:1,000 dilution) or the
laboratory-generated WA30 antibody (50) (1:2,000 dilution).
Pharmacological inhibitors. Glial cell cultures were treated with the following
experimentally determined concentrations of inhibitors for 24 h prior to all
analyses: Src inhibitor PP2, 0.5 nM (Calbiochem, San Diego, CA); ErbB2 inhibitor AG825, 4.0 g/ml (Calbiochem); FAK/paxillin inhibitor echistatin, 2.0 g/ml
(Sigma, St. Louis, MO).
shRNA constructs and lentiviral delivery. Mouse gene-specific lentiviral plasmids for Src (GenBank accession no. NM_009271; TRCN0000023595 and
TRCN0000023598), Fak (NM_007982), paxillin (NM_133915), and ErbB2
(NM_109715) small hairpin RNAs (shRNAs) were commercially purchased
(Sigma). Corresponding lentiviruses were produced as previously described (54),
and the most effective silencing construct was selected for further study. Briefly,
293T cells were transfected with Src.shRNA, FAK.shRNA, Pxn.shRNA, and
ErbB2.shRNA lentiviral plasmids or a control vector (pLKO1-GFP plasmid;
courtesy of Sheila Stewart, Washington University), using Fugene HD (Roche,
Mannheim, Germany). Lentiviruses were harvested at 48 and 72 h posttransfection. WT and Nf2⫺/⫺ glia were infected for a total of 48 h. WT and Nf2⫺/⫺ glia
were serum starved for 24 h prior to each experiment.
Thymidine incorporation assay. Glial cells were seeded at 5 ⫻ 104 cells per
well for 24 h of serum starvation. [3H]thymidine (1 Ci per well) was added in
serum-free medium, and the number of counts per minute was determined after
24 h.
Cell attachment, apoptosis, and cell adhesion. Cell attachment was measured
by seeding 5 ⫻ 104 Nf2flox/flox glial cells treated with Ad5-LacZ (WT) and
Ad5-Cre (Nf2⫺/⫺) into 96-well plates precoated with 10 g/ml fibronectin
(Gibco) following 24 h in serum-free medium. After 4 hours, the wells were
washed with 1⫻ phosphate-buffered saline (PBS) and incubated in 0.5% crystal
violet for 30 min. The number of attached cells was determined by extraction in
1% sodium dodecyl sulfate (SDS) overnight and spectrophotometric analysis at
540 nm.
Apoptosis was measured by seeding WT and Nf2⫺/⫺ glial cells into 24-well
plates, followed by preincubation in serum-free medium in the presence and
absence of 5 nM staurosporine (Sigma) for 24 h. Cells were then immunostained
with cleaved caspase-3 antibody (1:500 dilution; Cell Signaling Technology) and
1% bis-benzimide–PBS solution. The number of apoptotic cells was determined
by the fraction of caspase-3-positive cells relative to the total number of DAPI
(4⬘,6-diamidino-2-phenylindole)-positive cells. Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) was also used to
detect apoptosis levels in vivo. TUNEL labeling of Nf2GFAPCKO and Nf2flox/flox
mouse brain sections was performed using a commercially available fluoresceinbased in situ cell death detection kit (Roche) according to the manufacturer’s
instructions. The number of TUNEL-positive cells in the hippocampus was
determined by direct cell counting.
The formation of adherens junctions was assessed by ␤-catenin immunostaining as previously described (28). WT and Nf2⫺/⫺ glial cells were grown to
confluence and serum starved for 24 h. The cells were then permeabilized and
fixed by incubation in 3% paraformaldehyde–0.1% Triton X-100 in PBS for 10
min. Cells were blocked in PBS plus 10% goat serum and incubated with anti␤-catenin antibodies (1:200 dilution; Chemicon) and then with secondary antibody (1:200 dilution; Alexa). A 1.0% bis-benzimide solution was used to counterstain nuclei. Images were acquired on an inverted fluorescence microscope
(Eclipse TE300 inverted microscope; Nikon, Japan) equipped with a digital
camera (Optronics, Goleta, CA).
Merlin reexpression. To reintroduce merlin into WT and Nf2-deficient glia,
murine stem cell virus (MSCV) retroviral transduction was used to express either
WT merlin or an inactive mutant merlin protein containing a nonfunctional
patient missense mutation (L64P), as previously described (49, 62). MSCVmerlin and MSCV-merlin-L64P viral constructs were generated by cloning the
human NF2 cDNA into the MSCV-green fluorescent protein (MSCV-GFP)
vector. MSCV-merlin, MSCV-merlin-L64P, and the control (empty MSCV-GFP
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presence of 2 Ci [35S]methionine (1,000 Ci/mmol at 10 mCi/ml; Perkin-Elmer,
Waltham, MA). The first set of experiments were direct binding experiments in
which 75% of each TnT preparation containing radiolabeled merlin or Src was
incubated with 1.0 g recombinant His-tagged ErbB2 or Src protein (Invitrogen,
Carlsbad, CA) overnight at 4°C. ErbB2.His/merlin, ErbB2.His/Src, and Src.His/
merlin reaction mixtures were then incubated with His-Select nickel affinity gel
(Sigma) for 4 h at 4°C. The nickel affinity gel was washed and eluted with 2⫻
Laemmli buffer. Bound proteins along with the remaining original 25% of each TnT
reaction mixture were then separated by SDS-PAGE and analyzed by autoradiography. Densitometric analysis was performed using Gel-Pro Analyzer 4.0 software
(MediaCybernetics), with 25% of each TnT preparation serving as the input control
for normalization. The second set of experiments were competition binding assays in
which 1.0 g of recombinant His-tagged ErbB2 protein was incubated with radiolabeled Src in the presence of increasing amounts of nonradiolabeled in vitro TnTgenerated merlin or merlin fragments (none or a 1⫻, 5⫻, or 10⫻ excess of merlin
or merlin fragments relative to Src). Complementary experiments using increasing
amounts of nonradiolabeled Src (none or a 1⫻, 5⫻, or 10⫻ excess of Src relative to
merlin) were also performed. As described above, each reaction mix was incubated
with His-Select nickel affinity gel, followed by SDS-PAGE, autoradiography, and
densitometric analyses.
In vivo Src inhibition. Nf2GFAPCKO mice were generated by successive intercrossing of Nf2flox/flox and Nf2flox/wt; GFAP-Cre mice, and merlin expression in the
brain was detected by Western blotting using merlin antibodies (NF2 C-18;
1:1,000 dilution). Ten-day-old Nf2flox/flox (WT) and Nf2GFAPCKO (Nf2⫺/⫺) mice
(n ⫽ 4 per experimental group) received 2 mg/kg of body weight of PP2 (Cal-

FIG. 2. Merlin regulates glial cell growth in vivo. (A) Immunoblot analysis of merlin expression in Nf2flox/flox and Nf2GFAPCKO
mouse brain lysates also demonstrates a ⬎90% reduction in merlin
expression in Nf2GFAPCKO mice, as assessed by scanning densitometry. ␣-Tub, ␣-tubulin. (B) Representative immunofluorescence
photomicrographs of hippocampi from BrdU-injected Nf2flox/flox
and Nf2GFAPCKO mice labeled with both BrdU (green) and GFAP
(red) antibodies. Nf2GFAPCKO mouse brains had 2.2-fold more
BrdU-positive cells than Nf2flox/flox mouse brains. *, P ⬍ 0.001
(unpaired t test). (C) Representative photomicrographs of hippocampi from Nf2flox/flox and Nf2GFAPCKO mice labeled with GFAP
antibodies. Nf2GFAPCKO mouse brains had a 2.4-fold increase in
the number of GFAP-expressing cells compared to Nf2flox/flox mouse
brains. *, P ⫽ 0.001 (unpaired t test). (D) Representative photomicrographs of in vivo TUNEL staining of hippocampi from Nf2flox/flox
and Nf2GFAPCKO mouse brains, revealing no significant differences
in the number of apoptotic cells between Nf2GFAPCKO and
Nf2flox/flox mice.
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FIG. 1. Merlin regulates glial cell growth in vitro. (A) Immunoblot
analysis of merlin expression in primary glial cell lysates demonstrates
a ⬎95% reduction in merlin expression in Nf2⫺/⫺ glia (Ad5-Cre treatment) relative to that in WT glia (Ad-LacZ treatment), as assessed by
scanning densitometry. ␣-Tub, ␣-tubulin. (B) Nf2⫺/⫺ glia exhibited a
2.3-fold increase in proliferation relative to WT glia, as determined by
[3H]thymidine incorporation. *, P ⬍ 0.001 (unpaired t test). (C) WT
and Nf2⫺/⫺ glial cells were seeded in fibronectin-coated plates, and the
number of adherent cells was determined using a spectrophotometric
assay. No differences in cell attachment were observed between WT
and Nf2⫺/⫺ glial cells. OD, optical density. (D) WT and Nf2⫺/⫺ glial
cells were immunostained with cleaved caspase-3 antibody in the presence and absence of staurosporine (5 nM). No differences in apoptosis
were observed between WT and Nf2-deficient glial cells in either the
presence or absence of staurosporine. (E) ␤-Catenin staining along cell
contact junctions in WT and NF2⫺/⫺ glial cells revealed similar patterns by immunofluorescence microscopy.
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FIG. 3. Expression of WT but not mutant merlin reduces Nf2⫺/⫺ glial cell proliferation in vitro. (A) Immunoblot analysis of merlin expression in WT and
Nf2⫺/⫺ glia infected with empty MSCV, MSCV containing WT merlin (MSCV.NF2), or MSCV containing mutant merlin (MSCV.NF2.L64P). ␣-Tubulin
(␣-Tub) protein expression was used as an internal control for equal protein loading in all Western blot analyses. (B) Merlin reintroduction reduces the increased
proliferation observed in Nf2⫺/⫺ glia to WT levels, whereas the reintroduction of mutant (L64P) merlin has no effect. *, P ⬍ 0.003 (unpaired t test).

Downloaded from http://mcb.asm.org/ on January 11, 2014 by guest

biochem) in dimethyl sulfoxide or the same volume of dimethyl sulfoxide alone
by intraperitoneal injection three times a week for 2 weeks, as previously described (15).
Immunohistochemistry. To analyze proliferation in vivo, 7- to 10-day-old
Nf2flox/flox and Nf2GFAPCKO mice (n ⫽ 3) were injected with 5-bromo-2-deoxyuridine (BrdU; Sigma) (50 g/g of body weight) as previously described (24).
After 2 hours, mice were euthanized and their brains were removed. A quarter
of each brain was separated for immunoblot analyses, and the remainder of each
brain was fixed in 4% paraformaldehyde and paraffin sections prepared. Brain
sections were immunolabeled with BrdU (Abcam, Cambridge, MA) (1:100 dilution) and GFAP (Sigma) (1:200 dilution) antibodies followed by Alexa 488
(BrdU; Abcam) (1:200 dilution)- and Cy3 (GFAP; Sigma) (1:500 dilution)conjugated secondary antibodies. All sections were photographed with a digital
camera (Optronics) attached to an inverted microscope (Nikon). The number of
BrdU-positive cells in the hippocampus for each set of three littermates was
determined by direct cell counting.
To quantitate glial cell numbers in vivo, GFAP immunohistochemistry (Sigma)
(1:200 dilution) with Vectastain ABC development (Vector Laboratories, Burlingame, CA) was performed as previously reported (2). The number of GFAPpositive cells in the hippocampus for each set of three littermates was determined
by direct cell counting.

RESULTS
Merlin regulates glial cell growth in vitro and in vivo. To
study merlin growth regulation in CNS glia, we employed primary neonatal forebrain glial cultures from Nf2 conditional
knockout (Nf2flox/flox) mice, in which the expression of merlin is
eliminated by adenoviral delivery of Cre recombinase (AdCre). Following Cre recombinase transduction, Nf2⫺/⫺
(Nf2flox/flox ⫹ Ad-Cre) glia consistently demonstrated a ⬎95%
decrease in merlin expression compared to Nf2flox/flox glia
transduced with Ad-LacZ virus (WT) (Fig. 1A). As previously
reported for other cell types, Nf2⫺/⫺ glia exhibited a 2-fold
increase in proliferation compared to WT glia by thymidine
incorporation assay (mean ⫽ 2.3-fold increase) (Fig. 1B). Identical results were obtained using BrdU incorporation in vitro
(data not shown). In contrast, Nf2⫺/⫺ glia were indistinguishable from WT glia with respect to cell attachment (Fig. 1C),
apoptosis (Fig. 1D), and adherens junctions (Fig. 1E).
To determine whether our findings using Nf2-deficient glia
in vitro were also observed in the intact brain in vivo, we
analyzed glial cell proliferation in Nf2GFAPCKO mice.
Nf2GFAPCKO mice were generated by the successive intercrossing of Nf2flox/flox mice with Nf2flox/wt; GFAP-Cre mice to
yield mice with Nf2 loss in GFAP-expressing cells (glia).
Nf2GFAPCKO mice were born at the expected Mendelian frequencies, were phenotypically normal, and demonstrated a

FIG. 4. Merlin regulates Src activation in Nf2⫺/⫺ glial cells. (A) Rac1
activation assay shows similar Rac1 activities in WT and Nf2⫺/⫺ glial cell
lysates. Immunoblot analyses using phospho-specific MAPK and AKT antibodies demonstrated no change in MAPK or AKT activation in Nf2⫺/⫺ glia
compared to WT glia in vitro. Total Rac1, MAPK, and AKT expression levels
were used as internal controls for equal protein loading. ␣-Tub, ␣-tubulin.
(B) Immunoblot analysis of Src activation in WT and Nf2-deficient (Nf2⫺/⫺)
glia, using phospho-specific Src antibodies (specific for phosphorylation at
Y416, Y215, and Y527). Nf2⫺/⫺ glia exhibited a 6.7-fold increase in Src
activation at tyrosine 416 compared to WT glia, with no change in Src phosphorylation at tyrosine 215 or tyrosine 527. (C) Nf2GFAPCKO mouse brains
also show increased activation of Src (2.9-fold) compared to Nf2flox/flox mouse
brains, as assessed by immunoblot analyses and scanning densitometry. (D) In
a Src kinase activity assay, Nf2⫺/⫺ glia exhibited a 4.7-fold increase in Src
activity relative to WT glia. *, P ⬍ 0.001 (unpaired t test). OD, optical density.
(E) WT but not mutant merlin reduces Src activation in Nf2⫺/⫺ glia.
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⬎90% decrease in merlin expression in the brain compared to
Nf2flox/flox mice (Fig. 2A). Despite efficient Nf2 inactivation in
glia throughout the neuroaxis, these mice did not develop
nervous system tumors, even after 15 months of age (n ⫽ 15
mice to date).
To measure glial cell proliferation in vivo, postnatal day 10
Nf2GFAPCKO pups were injected with BrdU, and the numbers
of BrdU- and GFAP-positive glia were quantitated. Consistent
with our findings in vitro, we observed a 2-fold increase in the
numbers of BrdU-positive cells and GFAP-expressing cells in
Nf2GFAPCKO mice compared to those in Nf2flox/flox controls
(mean ⫽ 2.2- and 2.4-fold increases, respectively) (Fig. 2B and
C). No in vivo changes in apoptosis were observed in the
hippocampus for Nf2GFAPCKO mice compared to Nf2flox/flox
controls (Fig. 2D).
To demonstrate that the observed increase in cell proliferation was directly related to merlin expression, we restored
merlin expression in Nf2-deficient glia by MSCV retroviral
transduction. For these experiments, we reintroduced either
WT merlin (NF2) or an inactive merlin protein containing a
nonfunctional patient missense mutation (NF2.L64P) (4) into
WT and Nf2⫺/⫺ glia. Following transduction, the levels of
merlin expression in Nf2⫺/⫺ glia were similar to those observed
in WT glia (Fig. 3A). Consistent with the notion that merlin
directly regulates cell growth in glia, the reintroduction of WT
but not mutant merlin reduced the proliferation of Nf2⫺/⫺ glia
to the levels observed in WT glia (Fig. 3B). No effect of merlin
expression was observed on WT glial cell proliferation. Collec-

tively, these results demonstrate that merlin is a direct regulator of glial cell growth in vitro and in vivo.
Merlin regulates glial cell growth in a Src-dependent fashion. Previous studies using different primary cell types and
established cell lines have shown that merlin regulates several
distinct signaling pathways. To identify the signaling pathway
responsible for merlin growth regulation in glia, we employed
activity assays and activation (phospho-)-specific antibodies to
determine which of these previously implicated NF2-associated signaling pathways were deregulated in Nf2⫺/⫺ glia. In
contrast to previous reports using non-CNS cell types, no
changes in Rac1, MAPK, and AKT activation were observed in
Nf2⫺/⫺ compared to WT glia (Fig. 4A). However, we found
that Nf2⫺/⫺ glia exhibited hyperphosphorylation of the Src
nonreceptor tyrosine kinase oncoprotein on tyrosine 416, a
residue located within the Src kinase domain activation loop
(45) (Fig. 4B). No changes in Src phosphorylation were seen
on another common activation site (tyrosine 215) or on the
deactivation site (tyrosine 527). We also examined Src phosphorylation in lysates from Nf2GFAPCKO mice and found that
Src tyrosine 416 phosphorylation was likewise increased in
Nf2GFAPCKO mice relative to that in control mice in vivo (Fig.
4C). To directly demonstrate that Src activity was increased in
Nf2⫺/⫺ glia, we assayed Src activity following Src immunoprecipitation. Similar to the results obtained with the Src Y416
phospho-antibody, we observed a 4.7-fold increase in Src activity in Nf2⫺/⫺ glia relative to that in their WT counterparts
(Fig. 4D). Finally, to demonstrate that merlin directly regulates
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FIG. 5. Src inhibition restores Nf2⫺/⫺ glial cell proliferation to WT levels in vitro. (A) The PP2 Src inhibitor blocks Src activation in Nf2⫺/⫺
glia. (B) PP2 treatment eliminates the growth advantage observed in Nf2⫺/⫺ glia, as measured by [3H]thymidine incorporation. *, P ⬍ 0.001
(unpaired t test). (C) Immunoblot analysis of Src expression and activation in WT and Nf2⫺/⫺ glia following infection with Src.shRNA or vector
(pLK01-GFP) demonstrates ⬎90% inhibition of Src expression and activation after Src.shRNA treatment, as assessed by scanning densitometry.
Total Src or tubulin (␣-Tub) protein expression was used as an internal control for equal protein loading. (D) Src.shRNA treatment eliminates
the growth advantage observed in Nf2⫺/⫺ glia, as measured by [3H]thymidine incorporation *, P ⬍ 0.001 (unpaired t test).
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FIG. 6. Merlin regulates phosphorylation of the Src effectors FAK
and paxillin. (A) Immunoblot analyses of WT and Nf2⫺/⫺ glial lysates
following phosphotyrosine (pTyr) affinity binding with antibodies
against p130CAS, Ack1, and CASPR show no change in the phosphorylation state of these Src effectors. Merlin and ␣-tubulin (␣-Tub)
expression levels are included as internal controls. (B) Nf2-deficient
(Nf2⫺/⫺) glia demonstrated a 4.9-fold increase in FAK (Y576/577)
phosphorylation and a 5.5-fold increase in paxillin (Pxn) phosphorylation (Y118) (left). Nf2GFAPCKO mouse brains also showed increased
activation of FAK (2.2-fold) and paxillin (2.5-fold) compared to
Nf2flox/flox mouse brains, as assessed by immunoblot analyses and scanning densitometry (right). (C) WT but not mutant merlin inhibits both
FAK and paxillin phosphorylation in Nf2⫺/⫺ glia. (D) The Src inhibitor
PP2 (left) as well as Src.shRNA silencing (right) reverses the hyperphosphorylation of both FAK and paxillin in Nf2⫺/⫺ glia.

Nf2⫺/⫺ glia to WT levels (Fig. 7A, lower panel). No effect of
echistatin treatment on WT glial cell proliferation was observed. We next performed complementary experiments using
specific FAK (FAK.shRNA) and paxillin (Pxn.shRNA)
shRNA reagents to circumvent the problems inherent in using
relatively nonselective pharmacological inhibitors. In these experiments, lentiviral FAK.shRNA expression in Nf2⫺/⫺ glia
inhibited paxillin phosphorylation but had no effect on Src
phosphorylation (Fig. 7B, upper panel). FAK shRNA inhibition in Nf2⫺/⫺ glia also reduced the proliferation to levels
observed in WT glia (Fig. 7B, lower panel). In addition, we
inhibited paxillin expression in Nf2⫺/⫺ glia with lentiviral
Pxn.shRNA and observed no effect on either Src or FAK
phosphorylation (Fig. 7C, upper panel); however, this reduced
the proliferation of Nf2⫺/⫺ glia to WT levels (Fig. 7C, lower
panel). In both cases, no effects of FAK and paxillin inhibition
on WT glial cell proliferation were observed. These experiments demonstrate that merlin negatively regulates glial cell
proliferation in a Src-, FAK-, and paxillin-dependent manner
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Src activity, we assessed Src Y416 phosphorylation following
the reexpression of merlin. In these experiments, WT but not
mutant (NF2.L64P) merlin reexpression in Nf2⫺/⫺ glia resulted in a reduction of Src Y416 phosphorylation to the levels
observed in WT glia (Fig. 4E).
To determine whether Src hyperactivation resulting from
merlin loss was responsible for the increased proliferation seen
in Nf2-deficient glia, we treated WT and Nf2⫺/⫺ cells with PP2,
a potent inhibitor of the Src family of kinases (23). PP2 treatment resulted in a ⬎90% reduction in Src activity, as assessed
using Src phospho-specific antibodies (Fig. 5A), and was sufficient to reduce the proliferation of Nf2⫺/⫺ glia to WT levels
(Fig. 5B). No effect of PP2 treatment on WT glial cell proliferation was observed. To complement these findings, we utilized shRNA interference to silence Src expression. Nf2⫺/⫺
glia infected with Src.shRNA lentivirus exhibited a ⬎90% reduction in Src expression, as assessed using total and Src activation-specific antibodies (Fig. 5C), and similar to the case for
PP2 treatment, the shRNA decreased Nf2⫺/⫺ glial cell proliferation to WT levels (Fig. 5D). Similar results were obtained
using a second, independent Src.shRNA lentivirus (data not
shown). In all cases, no effect of Src.shRNA on WT glial cell
proliferation was observed. Together, these results demonstrate that merlin regulation of glial cell growth requires Src
Y416 phosphorylation and activation.
Src-mediated merlin regulation of glial cell growth requires
FAK and paxillin. To determine how Src regulates glial cell
growth, we next examined the activation of known Src downstream effector molecules, including FAK, paxillin, p130CAS,
Ack1, and CASPR. While we found no change in the phosphorylation status of p130CAS, Ack1, and CASPR in Nf2⫺/⫺
versus WT glia (Fig. 6A), we found increased FAK tyrosine
576/577 and paxillin tyrosine 118 phosphorylation in Nf2⫺/⫺
glia relative to their WT counterparts (Fig. 6B, left panels).
Similarly, immunoblot analysis of Nf2GFAPCKO mouse brain
lysates demonstrated increased FAK and paxillin phosphorylation relative to that in control littermates (Fig. 6B, right
panels).
To demonstrate that merlin loss and Src activation were
directly responsible for the increases in FAK and paxillin phosphorylation, we transduced WT and Nf2⫺/⫺ glia with WT or
mutant (L64P) merlin, using MSCV retroviral delivery. In
these experiments, reexpression of WT but not mutant merlin
in Nf2⫺/⫺ glia reduced FAK and paxillin phosphorylation to
WT levels (Fig. 6C). To demonstrate that Src activation was
responsible for FAK and paxillin activation in Nf2⫺/⫺ glial
cells, we employed PP2 pharmacologic Src inhibition and
shRNA Src silencing (Src.shRNA). Both PP2 (left panels) and
Src.shRNA (right panels) inhibition reduced FAK and paxillin
phosphorylation in Nf2⫺/⫺ glial cells to WT levels (Fig. 6D).
No effect of merlin expression, PP2 treatment, or Src.shRNA
lentiviral infection was observed on FAK and paxillin phosphorylation in WT glia.
To determine whether FAK and paxillin were responsible
for the increased proliferation observed in Nf2-deficient glia,
we initially used a known FAK/paxillin pharmacological inhibitor, echistatin (11). Treatment of Nf2⫺/⫺ glia with echistatin
resulted in inhibition of FAK and paxillin phosphorylation but
had no effect on Src phosphorylation (Fig. 7A, upper panel).
Furthermore, echistatin treatment reduced the proliferation of
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and place paxillin downstream of Src and FAK in the merlin
glial cell growth control pathway.
Merlin regulates glial cell proliferation through Src signaling in vivo. To demonstrate that merlin regulates glial cell
proliferation in a Src-dependent manner in vivo, postnatal day
10 Nf2GFAPCKO pups were injected with either the Src inhibitor PP2 or vehicle three times a week for 2 weeks (14).
Nf2GFAPCKO pups were then injected with BrdU, and the
numbers of BrdU- and GFAP-positive glia were quantitated as
previously reported (3, 24). Consistent with our findings in
vitro, PP2 treatment of Nf2GFAPCKO mice resulted in reductions in the numbers of BrdU (Fig. 8A)- and GFAP (Fig.
8B)-expressing cells to levels observed in Nf2flox/flox mice. Similarly, PP2 treatment decreased Src, FAK, and paxillin phosphorylation in Nf2GFAPCKO mice to WT levels (Fig. 8C). PP2
treatment had no effect on glial cell numbers, proliferation, or
Src pathway activity in Nf2flox/flox mice. Collectively, these results demonstrate that merlin also regulates glial cell growth in
a Src-dependent manner in vivo.
Merlin regulates Src by modulating ErbB2 activation. Several receptor tyrosine kinase proteins have been shown to
regulate Src activity, including ErbB2 (erythroblastic leukemia
viral oncogene homolog 2) (36, 53) and EGFR (13, 19). Based
on previous studies implicating EGFR in merlin growth regu-

lation in non-nervous-system cells (9), we first examined
EGFR in Nf2⫺/⫺ glia in vitro and in Nf2GFAPCKO mice in vivo.
We found no changes in EGFR expression or phosphorylation
in Nf2⫺/⫺ glia relative to that in WT glia (Fig. 9A). Next, we
examined the activation status of other members of the EGFR
family, including ErbB2, ErbB3, and ErbB4, using phosphospecific antibodies. Whereas we observed no changes in ErbB3
or ErbB4 tyrosine phosphorylation (Fig. 9B), we observed a
significant increase in ErbB2 phosphorylation on tyrosine 877
in Nf2⫺/⫺ glial cells compared to that in WT glia (Fig. 9C). In
contrast, no change in ErbB2 tyrosine 1248 phosphorylation
was observed in Nf2⫺/⫺ glial cells relative to that in WT glia
(Fig. 9C). As expected, we also detected increased ErbB2
tyrosine 877 phosphorylation in Nf2GFAPCKO compared to
Nf2flox/flox mouse brains (Fig. 9D). To directly demonstrate that
ErbB2 activity was increased in Nf2⫺/⫺ glia, we assayed ErbB2
activity following ErbB2 immunoprecipitation. Similar to the
results obtained with the ErbB2 Y877 phospho-antibody, we
observed a 3.2-fold increase in ErbB2 activity in Nf2⫺/⫺ glia
relative to that in their WT counterparts (Fig. 9E). Lastly, to
show that merlin is directly responsible for ErbB2 activation,
we found that reexpression of WT but not L64P mutant merlin
in Nf2⫺/⫺ glia reduced ErbB2 Y877 phosphorylation to WT
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FIG. 7. Merlin growth regulation requires FAK and paxillin signaling. (A) (Top) Echistatin inhibits the phosphorylation of both FAK and
paxillin but has no effect on Src activation. (Bottom) Echistatin treatment eliminates the growth advantage observed in Nf2⫺/⫺ glia, as determined
by [3H]thymidine incorporation. *, P ⬍ 0.001 (unpaired t test). (B) (Top) FAK.shRNA inhibits the expression of FAK (⬎92% reduction) as well
as the phosphorylation of both FAK and paxillin. No effect on Src activation was observed. (Bottom) FAK.shRNA treatment eliminates the growth
advantage observed in Nf2⫺/⫺ glia, as assessed by [3H]thymidine incorporation. *, P ⬍ 0.003 (unpaired t test). (C) (Top) Pxn.shRNA treatment
inhibits the expression of paxillin (⬎95% reduction) as well as the phosphorylation of paxillin but has no effect on FAK and Src activation. Total
tubulin, Src, FAK, and paxillin expression levels were used as internal controls for equal protein loading. (Bottom) Pxn.shRNA treatment
eliminates the growth advantage observed in Nf2⫺/⫺ glia, as determined by [3H]thymidine incorporation. *, P ⬍ 0.001 (unpaired t test).
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levels (Fig. 9F). No effect of merlin expression on ErbB2 Y877
phosphorylation was observed in WT glia.
Consistent with ErbB2 activation as the initiating signal in
the merlin growth control pathway, inhibition of Src or Src
effectors in vitro or in vivo had no effect on ErbB2 Y877
phosphorylation. In these studies, no changes in ErbB2 tyrosine 877 phosphorylation were seen following PP2 treatment
of Nf2⫺/⫺ glia in vitro (Fig. 10A, left panels), PP2 treatment of
Nf2GFAPCKO mouse brains in vivo (Fig. 10A, right panels),
inhibition of FAK and paxillin by echistatin (Fig. 10B), or
shRNA genetic inhibition of Src (Fig. 10C), FAK (Fig. 10D),
and paxillin (Fig. 10E).
To determine whether merlin-dependent ErbB2 activation
was responsible for Src-FAK-paxillin pathway activation as
well as increased proliferation in Nf2⫺/⫺ glia, we initially employed the ErbB2-specific inhibitor tyrphostin (AG825) (39).
Following treatment of Nf2⫺/⫺ glia with AG825, Src, FAK, and
paxillin phosphorylation in Nf2⫺/⫺ glial cells was reduced to
WT levels (Fig. 11A, top panel). Similarly, ErbB2 inhibition
also decreased Nf2⫺/⫺ glial cell growth to the levels observed
in WT glia (Fig. 11A, bottom panel). To provide additional
evidence for the role of ErbB2 in merlin growth regulation, we
employed ErbB2 silencing with lentiviral ErbB2.shRNA. In
these experiments, loss of ErbB2 expression likewise reduced

Src, FAK, and paxillin phosphorylation in Nf2⫺/⫺ glia to WT
levels (Fig. 11B, top panel). As observed following AG825
treatment, ErbB2 shRNA inhibition also decreased Nf2⫺/⫺
glial cell growth to WT levels (Fig. 11B, bottom panel). These
findings demonstrate that merlin selectively regulates ErbB2
activation, which is responsible for the increased Src signaling
and proliferation observed in Nf2⫺/⫺ glial cells.
Merlin regulates the interaction between Src and ErbB2.
Based on the observation that ErbB2 can interact with both
merlin (15) and Src (27, 36, 42), we next sought to determine
whether merlin loss is associated with increased ErbB2-Src
binding. In these experiments, ErbB2 was precipitated from
WT and Nf2⫺/⫺ glia using total ErbB2 antibodies. First, we
confirmed that merlin binds to ErbB2 in WT glia and demonstrated that merlin loss in glia leads to a dramatic increase in
both total and Y416-phosphorylated Src binding to ErbB2
(Fig. 12A). Second, we showed that the reintroduction of WT
but not mutant merlin inhibited ErbB2-Src binding (Fig. 12B).
Third, we found that inhibition of ErbB2 activation using the
AG825 inhibitor blocked the interaction of ErbB2 with Src in
Nf2⫺/⫺ glia (Fig. 12C), whereas inhibition of Src activation
with PP2 had no effect on ErbB2-Src binding (Fig. 12D). These
findings demonstrate that only functional merlin can inhibit
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FIG. 8. Merlin regulation of glial cell growth is Src dependent in vivo. (A) Representative immunofluorescence photomicrographs of hippocampi from BrdU-injected Nf2flox/flox and Nf2GFAPCKO mice, with or without treatment with the Src inhibitor PP2 (2 mg/kg). Images were
labeled with both BrdU (green) and GFAP (red) antibodies. A twofold decrease in the number of BrdU-positive cells was observed in the
PP2-treated Nf2GFAPCKO brains compared to vehicle-treated mouse brains. *, P ⫽ 0.001 (unpaired t test). (B) Representative photomicrographs
of hippocampi labeled with GFAP antibodies. PP2-treated Nf2GFAPCKO mice exhibited a twofold decrease in the number of GFAP-labeled cells
compared to vehicle-treated Nf2GFAPCKO littermates. No effect of PP2 treatment on Nf2flox/flox mice was seen. *, P ⬍ 0.002 (unpaired t test).
(C) Immunoblot analysis demonstrates amelioration of the increased Src, FAK, and paxillin activation following PP2 treatment. The expression
levels of tubulin, total Src, FAK, and paxillin were used as internal controls for equal protein loading.
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Src binding to ErbB2 and that the association between Src and
ErbB2 is dependent on ErbB2 but not Src activity.
To determine whether ErbB2 binding to merlin and Src
represents a direct interaction, we immunoprecipitated radiolabeled in vitro-transcribed/translated merlin and Src proteins
with a recombinant ErbB2 protein containing the activation
region of ErbB2 known to interact with Src (27). Both merlin
and Src directly interacted with ErbB2 (Fig. 12E). Importantly,
we observed no binding of mutant merlin (L64P) to ErbB2,
consistent with its inability to restore normal growth regulation
in Nf2⫺/⫺ glia. We next sought to determine whether merlin
and Src compete for binding to ErbB2. In these experiments,
excess amounts of merlin or Src were added to interfere with
Src-ErbB2 or merlin-ErbB2 binding, respectively. We show
that merlin inhibited ErbB2-Src binding and Src inhibited
ErbB2-merlin binding in a concentration-dependent manner
(Fig. 12F and G).
To validate the Src-ErbB2 association results, we performed

reciprocal immunoprecipitation studies, using Src to detect
ErbB2 binding. In these experiments, we found that merlin loss
in glia led to a dramatic increase in Src binding to ErbB2 (Fig.
13A) and that reexpression of WT but not mutant merlin
inhibited ErbB2-Src binding (Fig. 13B). Moreover, the SrcErbB2 interaction was dependent only on ErbB2 activation
(Fig. 13C) and not Src activity (Fig. 13D). Interestingly, we also
noticed that merlin was found in the Src immunoprecipitates
from WT glial cells (Fig. 13A). However, unlike ErbB2-Src
binding, the interaction between Src and merlin was not dependent on Src or ErbB2 activity.
The finding that merlin can associate with either Src or
ErbB2 suggests two non-mutually exclusive models for merlin
function. First, merlin may compete with Src for binding to
ErbB2, such that merlin-ErbB2 binding precludes an association between Src and ErbB2. In this fashion, merlin loss allows
Src to bind to ErbB2, which culminates in Src activation and
increased glial cell growth. Second, merlin may bind to Src and
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FIG. 9. Merlin regulates ErbB2 activation in glial cells. (A) Immunoblot analysis of WT and Nf2⫺/⫺ glial lysates, using a phospho-specific
EGFR antibody (Y845), demonstrates no change in EGFR activation. Total EGFR expression was used as an internal control for equal protein
loading. (B) Immunoblot analyses of WT and Nf2⫺/⫺ glial lysates following phosphotyrosine (pTyr) affinity binding with antibodies against ErbB4
and ErbB3 show no change in phosphorylation state for the other two ErbB family members. Merlin and tubulin expression levels were included
as internal controls. (C) Nf2⫺/⫺ glia exhibited a 7.2-fold increase in ErbB2-Y877 activation compared to WT controls in vitro, with no change in
ErbB2-Y1248 phosphorylation. (D) Nf2GFAPCKO mouse brains exhibited a 2.3-fold increase in ErbB2 (Y877) activation compared to WT controls
in vivo, as assessed by immunoblotting analysis and scanning densitometry. (E) In an ErbB2 kinase activity assay, Nf2⫺/⫺ glia exhibited a 3.2-fold
increase in ErbB2 activity relative to WT glia. *, P ⬍ 0.001 (unpaired t test). OD, optical density. (F) WT but not mutant merlin expression reduces
ErbB2 activation in Nf2⫺/⫺ glia.
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FIG. 11. Merlin regulation of glial cell growth requires ErbB2 activation. (A) (Top) Inhibition of ErbB2 activation with AG825 in
Nf2⫺/⫺ glia reduces Src, FAK, and paxillin hyperactivation to WT
levels. (Bottom) AG825 treatment of Nf2⫺/⫺ glia reduces cell proliferation to WT levels, as assessed by [3H]thymidine incorporation. No
effect of AG825 treatment was observed in WT glia. *, P ⬍ 0.001
(unpaired t test). (B) (Top) Inhibition of ErbB2 expression and activation with ErbB2.shRNA (⬎98% reduction) reduces the hyperactivation of Src, FAK, and paxillin in Nf2⫺/⫺ glia to WT levels. Total
tubulin, Src, FAK, and ErbB2 expression levels were used as internal
loading controls. (Bottom) Treatment with ErbB2.shRNA but not with
vector eliminates the growth advantage observed in Nf2⫺/⫺ glia, as
assessed by [3H]thymidine incorporation. No effect of ErbB2.shRNA
was observed in WT glia. *, P ⬍ 0.002 (unpaired t test).

sequester Src from binding to ErbB2. The loss of merlin would
release Src to bind to ErbB2 and initiate Src-dependent signaling to increase glial cell proliferation.
To distinguish between these two possibilities, we sought to
define the merlin residues important for Src and ErbB2 binding. In these experiments, we employed an in vitro binding
assay using recombinant ErbB2 and Src proteins to determine
which regions of merlin were necessary for merlin-ErbB2 and
merlin-Src interactions. In vitro-transcribed/translated radiolabeled full-length merlin (WT) as well as merlin fragments
containing residues 1 to 300 (NF2.N-term), 300 to 595 (NF2.Cterm), and 300 to 557 were immunoprecipitated with recombinant ErbB2 or Src protein. Merlin binding to ErbB2 required
C-terminal domain residues 300 to 557 (Fig. 14A), whereas
merlin binding to Src required C-terminal domain residues 557
to 595 (Fig. 14B). These findings demonstrate that the residues
important for merlin binding to Src and ErbB2 are distinct and
separable.
Since the merlin C-terminal fragment containing residues
300 to 557 binds only to ErbB2 and not to Src, we took advantage of this selective binding to discriminate between the
two possible models of merlin function. We found that increasing amounts of the merlin C-terminal 300-557 fragment inhibited Src binding to ErbB2 (Fig. 14C). In contrast, increasing
amounts of Src did not inhibit the association between the
merlin C-terminal 300-557 fragment and ErbB2 (Fig. 14D).
These results indicate that merlin binding to ErbB2 precludes
the ability of Src to associate with ErbB2 and that the association between merlin and ErbB2 likely interferes with ErbB2mediated activation of Src.
DISCUSSION
In this report, we use GFAP-positive (glial) cells in vitro and
in vivo as a model system to define the mechanism underlying
merlin growth regulation in the CNS. First, we show that Nf2deficient glia exhibit increased proliferation, which is reversed
by merlin reexpression. Second, we demonstrate that merlin
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FIG. 10. ErbB2 activation functions upstream of Src/FAK/paxillin in the merlin glial control growth pathway. (A) PP2 treatment of Nf2⫺/⫺ glial
cells has no effect on ErbB2 hyperactivation in vitro or in vivo. (B) Echistatin treatment of Nf2⫺/⫺ glial cells has no effect on ErbB2 hyperactivation
in vitro. Genetic inhibition of Src (C), FAK (D), or paxillin (E) in Nf2⫺/⫺ glial cells, using Src.shRNA, FAK.shRNA, or Pxn.shRNA, respectively,
has no effect on ErbB2 hyperactivation. Total tubulin and total ErbB2 expression levels were used as internal loading controls.
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regulation of glial cell growth requires ErbB2 activation,
ErbB2-Src binding, and Src pathway activity in vitro and in
vivo. Third, based on the direct binding of merlin to Src and
ErbB2, we propose a molecular mechanism for merlin function
in glia in which merlin competitively inhibits the association
between Src and ErbB2. Importantly, although no visible tumors were observed in our Nf2 glial conditional knockout
mice, these results identify a critical targetable growth control
pathway in glia relevant to human NF2-associated glial cell
tumors.
The lack of glial tumors in the Nf2 glial conditional knockout
mice may reflect the generally low incidence of tumor formation in Nf2 conditional knockout GEM strains. In this regard,
the incidence of nervous system tumor formation in the schwannoma and meningioma Nf2 GEM models ranged between 24%

and 29%, with an average latency of 10 to 14 months (18, 26).
While we aged the Nf2GFAPCKO mice for 15 months and
performed detailed necropsies, it is possible that tumor formation will require larger numbers of mice and longer periods of
observation. Alternatively, it is possible that glial cell tumor
formation requires stromal Nf2 heterozygosity, as we have previously reported for NF1-associated optic gliomas in Nf1 optic
glioma GEM models (2, 3, 64). Future experiments are necessary to explore these possibilities.
Previous studies with other cell types have shown that Src
controls cell proliferation and motility by signaling through
downstream effectors, including FAK and paxillin (8). In
Nf2⫺/⫺ glia, we found that Src hyperactivation leads to the
sequential activation/phosphorylation of FAK and paxillin and
that Src, FAK, and paxillin are responsible for the increased

Downloaded from http://mcb.asm.org/ on January 11, 2014 by guest

FIG. 12. Merlin directly regulates the interaction between ErbB2 and Src. (A) Immunoprecipitation of ErbB2 from WT and Nf2⫺/⫺ glia shows
that the association between ErbB2 and Src as well as ErbB2 and p-Src (Y416) occurs only in Nf2-deficient glia. (B) WT but not mutant merlin
expression inhibits ErbB2 and Src interaction in Nf2⫺/⫺ glia. (C) AG825 treatment inhibits the association between ErbB2 and Src in Nf2-deficient
glia. (D) PP2 treatment has no effect on the association between ErbB2 and Src in Nf2-deficient glia. Total ErbB2 was used as an internal control
for ErbB2 precipitation. (E) Src and merlin directly associate with ErbB2 following immunoprecipitation of [35S]methionine-radiolabeled merlin
(NF2.WT or NF2.L64P) or Src proteins with recombinant His-tagged ErbB2 (ErbB2.His). (Top) No binding to ErbB2 was observed with mutant
merlin. (Middle) In the absence of the ErbB2 recombinant protein, there was no binding of radiolabeled NF2.WT, NF2.L64P, or Src protein to
the His affinity gel. (Bottom) Input levels of radiolabeled NF2.WT, NF2.L64P, and Src proteins in the ErbB2.His immunoprecipitation analysis
were used as normalization controls in scanning densitometric analyses to determine the percentages of bound proteins. A total of 32% of
radiolabeled NF2.WT and 28% of Src proteins were bound to recombinant ErbB2 protein, whereas ⬍1% of NF2.L64P was bound to ErbB2.
(F) (Top) ErbB2-Src binding was decreased 67% in the presence of equal amounts of merlin and completely eliminated in the presence of a fivefold
excess of merlin. (G) (Top) ErbB2-merlin binding was decreased 52% in the presence of equal amounts of Src, decreased 94% in the presence
of a 5-fold excess of Src, and completely eliminated in the presence of a 10-fold excess of Src (top). (Bottom [F and G]) Immunoblotting was used
to verify the amounts of nonradiolabeled merlin and Src added to each reaction mix.
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proliferation observed in Nf2-deficient glia in vitro and in vivo.
These findings are compatible with prior reports demonstrating that FAK and paxillin colocalize and physically associate
with merlin (15, 57). In addition, merlin reexpression in NF2deficient malignant mesothelioma cells has been found to attenuate FAK phosphorylation and to inhibit the interaction
between FAK and Src (41). While the exact mechanism underlying FAK growth regulation has not been elucidated fully,
recent evidence suggests that FAK may control cell growth by
suppressing p21 and p27 cyclin-dependent kinase inhibitor levels (6, 12). However, in preliminary experiments, we detected
no changes in p21 and p27 expression in Nf2⫺/⫺ glia relative to
WT glia (S. S. Houshmandi and D. H. Gutmann, unpublished
observations).
Our finding that paxillin is required for merlin growth control in glial cells is consistent with previous reports demonstrating that paxillin can regulate cell proliferation in other cell
types (22, 56). While the mechanism of paxillin growth regulation is not clear, paxillin may control cell growth by modulating the expression or activation of select transcription factors, such as AP-1 and c-Jun (56). We examined the expression
of these transcription factors, as well as others implicated in
growth control, by using RNA microarray profiling of WT and
Nf2⫺/⫺ glia and found no changes in the expression of relevant
transcription factors (Houshmandi and Gutmann, unpublished
observations). Studies are ongoing in our laboratory to determine the precise manner by which FAK and paxillin regulate
cell growth in CNS glia.

Src has been implicated in the control of many intracellular signaling pathways, initiated by cell surface receptor
activation, which regulate cell differentiation, survival, proliferation, and motility (58). Previous studies have shown
that the growth regulatory function of merlin may be mediated in a variety of different cell types by its interaction with
several cell surface receptors, including CD44, ␤1-integrin,
ErbB2, and EGFR (9, 15, 35, 38). While all of these receptors have been shown to regulate Src activity in other cell
types, only ErbB2 has been shown to form complexes with
CD44, EGFR, and ␤1-integrin. In this regard, ErbB2 represents a logical candidate for a cell surface receptor capable of integrating multiple environmental signals relevant to
merlin growth regulation. In this report, we demonstrate for
the first time that ErbB2 plays a critical role in regulating
Src-mediated proliferation in Nf2⫺/⫺ glia and that ErbB2 is
the main ErbB receptor kinase family member whose activation is deregulated by merlin loss in glial cells.
Consistent with the role of ErbB2 in controlling cell differentiation, survival, and growth, ErbB2 has been shown to interact with several molecules previously implicated in merlin
growth regulation in other cell types, including CD44. In this
regard, ErbB2 interacts with CD44 in ovarian carcinoma cell
lines and has been shown to regulate ovarian carcinoma cell
growth (63). In addition, ErbB2 also interacts with EGFR to
regulate glioma cell proliferation (28, 40) and motility (41). In
the present study, we show that ErbB2 is hyperactivated in
Nf2-deficient glia in vitro and in vivo and that pharmacologic
or genetic inhibition of ErbB2 in vitro reverses the growth
phenotype seen in Nf2⫺/⫺ glia. While the exact mechanism
underlying merlin regulation of ErbB2 activation is not known,
these findings raise the intriguing possibility that ErbB2 is a
central mediator of cell signaling and might integrate growth
regulatory messages from other cell membrane receptors. In
the absence of merlin, these receptor associations may not
form, leading to deregulated ErbB2 activation. In support of
this mechanism, preliminary studies in our laboratory have
recently shown that the interactions between ErbB2 and CD44,
ErbB2 and EGFR, and ErbB2 and another ErbB2 binding
partner, ErbB4, are all dramatically attenuated in Nf2⫺/⫺ glia
(Houshmandi and Gutmann, unpublished observations).
Finally, we show that merlin regulates ErbB2-mediated activation of Src. This observation is consistent with previous
studies which have shown that ErbB2 interacts with and activates Src in breast cancer cells and that ErbB2-Src binding is
specific to the catalytic domain of ErbB2 (27, 36). In Nf2⫺/⫺
glia, we found increased ErbB2-Src binding, which was blocked
by pharmacologic ErbB2 inhibition. It is worth noting that the
increase in Src and ErbB2 phosphorylation in Nf2-deficient
glia is limited to specific sites in the catalytic domain of each
protein (Src-Y416 and ErbB2-Y877) which have been predicted to regulate their activation and to mediate their interactions with other proteins (27). In this report, we demonstrate
that a recombinant ErbB2 cytoplasmic domain protein which
contains the activation region as well as the Src-interacting
domain directly interacts with merlin and Src in vitro and that
merlin competitively inhibits the interaction between Src and
ErbB2 in a concentration-dependent manner. We further show
that merlin binding to ErbB2 and Src involves different residues in the C terminus of the merlin protein. We took advan-
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FIG. 13. Merlin interacts with both ErbB2 and Src. (A) Immunoprecipitation of Src from WT and Nf2⫺/⫺ glia shows that the association between Src and ErbB2 occurs only in Nf2-deficient glia. (B) WT
but not mutant merlin expression inhibits Src and ErbB2 interaction in
Nf2⫺/⫺ glia. (C) AG825 treatment inhibits the association between Src
and ErbB2 in Nf2-deficient glia. (D) PP2 treatment has no effect on the
association between Src and ErbB2 in Nf2-deficient glia. Total Src was
used as an internal control for Src precipitations. In WT glia, merlin
and Src associate; however, this binding is not affected by SrbB2 or Src
activation.
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tage of this differential merlin binding to demonstrate that
merlin binding to ErbB2 blocks Src binding. Based on these
findings, we propose a novel mechanism for merlin function
(Fig. 14E). In WT cells, merlin binds to the cytoplasmic
domain of ErbB2 and precludes an association between Src
and ErbB2. However, in the absence of merlin, Src binds to
activated ErbB2, which results in increased Src activity, Src
effector activation, and increased cell growth. Our results demonstrating a central role for ErbB2 and Src in regulating NF2-

deficient glial cell growth suggest that potential therapeutic
approaches for treating NF2-associated tumors might involve
targeting ErbB2 and/or Src activation. With the recent success
employing ErbB2 inhibitors (e.g., trastuzumab) and Src kinase
inhibitors (e.g., dasatinib) in clinical studies for the treatment
of breast cancer (40, 43) and myelogenous leukemia (16, 31,
37), the future use of these and related inhibitors may prove
beneficial for the treatment of human tumors characterized by
merlin loss of function.
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FIG. 14. Merlin binding to ErbB2 precludes the association of Src with ErbB2. (A) In an in vitro binding assay, [35S]methionineradiolabeled full-length merlin containing residues 1 to 595 (NF2.WT), NF2.C-term containing residues 300 to 595, and NF2.C-term
containing residues 300 to 557, bound to recombinant His-tagged ErbB2 (ErbB2.His). In contrast, no binding to ErbB2 was observed using
NF2.N-term containing residues 1 to 300. Input levels for the reactions are shown and were used as normalization controls in scanning
densitometric analyses to determine the percentages of bound proteins. Thirty percent of radiolabeled NF2.WT, 25% of NF2.C-term, and
24% of NF2.300-557 bound to recombinant ErbB2 protein, whereas ⬍1% of NF2.N-term bound to ErbB2. (B) In an in vitro binding assay,
[35S]methionine-radiolabeled full-length merlin containing residues 1 to 595 (NF2.WT), and NF2.C-term containing residues 300 to 595,
bound to recombinant His-tagged ErbB2 (ErbB2.His). In contrast, no binding to ErbB2 was observed using either NF2.C-term containing
residues 300 to 557, or NF2.N-term containing residues 1 to 300. Input levels for the reactions are shown and were used as normalization
controls in scanning densitometric analyses to determine the percentages of bound proteins. Thirty-one percent of radiolabeled NF2.WT and
19% of NF2.C-term bound to recombinant Src protein, whereas ⬍1% of NF2.N-term and NF2.300-557 bound to Src. (C) (Top) ErbB2-Src
binding was decreased 48% in the presence of equal amounts of NF2.300-557, decreased 96% in the presence of a 5-fold excess of
NF2.300-557, and completely eliminated in the presence of a 10-fold excess of NF2.300-557. (Bottom) Coomassie staining was used to verify
the amount of nonradiolabeled NF2.300-557 added to each reaction mix. (D) (Top) NF2.300-557–ErbB2 binding was not altered by equal
or excess amounts of Src. (Bottom) Immunoblotting was used to verify the amount of nonradiolabeled Src added to the reaction mixtures.
(E) Potential molecular model for merlin growth regulation in glial cells. In WT cells, merlin associates with ErbB2 and precludes Src binding
to ErbB2. In the absence of functional merlin, Src binds to activated ErbB2, leading to ErbB2-mediated Src phosphorylation/activation, Src
effector protein phosphorylation, and increased glial cell growth.
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